Telmisartan Versus Ramipril After Acute Coronary Syndrome
Information source: Catholic University of the Sacred Heart
Information obtained from ClinicalTrials.gov on October 19, 2009
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Acute Coronary Syndrome; Myocardial Infarction; Coronary Disease
Intervention: TELMISARTAN (Drug); RAMIPRIL (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Catholic University of the Sacred Heart Official(s) and/or principal investigator(s):
Italo Porto, MD, PhD, Principal Investigator, Affiliation: Catholic University of the Sacred Heart
Luca Di Vito, MD, Principal Investigator, Affiliation: Catholic University of the Sacred Heart
Overall contact:
Italo Porto, MD, PhD, Phone: 0039(0)6-30154127, Email: i.porto@doctors.org.uk
Summary
The purpose of this study is to compare the antinflammatory and endothelial progenitor cell
(EPC) mobilizing effect of Ramipril and Telmisartan in patients presenting with acute
coronary syndrome
Clinical Details
Official title: Telmisartan vs Ramipril for Reduction of Inflammation and Recruitment of Endothelial Progenitor Cells After Acute Coronary Syndrome
Study design: Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Efficacy Study
Primary outcome: High sensitivity C-Reactive Protein
Secondary outcome: Endothelial Progenitor Cells
Eligibility
Minimum age: 40 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Biochemical evidence of myocardial infarction as indicated by elevation of cTnT,
- presence of ECG ischemic changes,
- angiographic evidence of a primary coronary event, such as plaque erosion and/or
rupture, fissuring, or dissection at coronary angiography,
- successful coronary revascularization of at least one culprit coronary vessel.
Exclusion Criteria:
- Age>80 years, current ACE inhibitor or ARB treatment,
- ejection fraction <35%, infarction secondary to ischemia due to an imbalance of O2
supply and demand,
- ECG abnormalities that could affect the recognition of ST segment shift,
- recent or chronic infective or inflammatory diseases,
- malignancy, and myocardial infarction,
- surgery or trauma in the previous month.
Locations and Contacts
Italo Porto, MD, PhD, Phone: 0039(0)6-30154127, Email: i.porto@doctors.org.uk
Catholic University of the Sacred Heart, Rome 00168, Italy; Recruiting
Italo Porto, MD, PhD, Email: i.porto@doctors.org.uk
Luca Di Vito, MD, Email: divitoluca@yahoo.it
Italo Porto, MD, PhD, Principal Investigator
Luca Di Vito, MD, Sub-Investigator
Additional Information
Catholic University
Related publications: Biasucci LM, Lombardi M, Piro M, Di Giannuario G, Liuzzo G, Crea F. Irbesartan significantly reduces C reactive protein concentrations after 1 month of treatment in unstable angina. Heart. 2005 May;91(5):670-1. No abstract available.
Starting date: November 2007
Ending date: November 2008
Last updated: June 19, 2008
|
